Cargando…
Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study
BACKGROUND: The current study aimed to evaluate growth and neurodevelopmental status in patients with retinopathy of prematurity (ROP) treated with intravitreal bevacizumab (IVB). METHODS: This historical cohort study was conducted on neonates with ROP who were treated with IVB and age and birth wei...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594208/ https://www.ncbi.nlm.nih.gov/pubmed/34784985 http://dx.doi.org/10.1186/s40942-021-00340-6 |
_version_ | 1784599922757074944 |
---|---|
author | Abrishami, Majid Boskabadi, Hassan Abrishami, Mojtaba Shekarchian, Farid Khadem-Rezaiyan, Majid Shoeibi, Nasser |
author_facet | Abrishami, Majid Boskabadi, Hassan Abrishami, Mojtaba Shekarchian, Farid Khadem-Rezaiyan, Majid Shoeibi, Nasser |
author_sort | Abrishami, Majid |
collection | PubMed |
description | BACKGROUND: The current study aimed to evaluate growth and neurodevelopmental status in patients with retinopathy of prematurity (ROP) treated with intravitreal bevacizumab (IVB). METHODS: This historical cohort study was conducted on neonates with ROP who were treated with IVB and age and birth weight-matched controls who did not need IVB. Apgar score less than five, history of blood transfusion and history of infectious diseases were among exclusion criteria. Indirect ophthalmoscopic examinations were performed till complete retinal vascularization. Growth and neurodevelopmental status were evaluated by Age and Stages Questionnaire (ASQ) at the ages of 6, 12, and 18 months. Developmental milestones were assessed in five areas (gross motor, fine motor, personal-social status, problem-solving, and relationship) and overall issues. RESULTS: A total of 34 cases and 36 controls were included in the present study. Birth weight and corrected gestational age were not statistically different between the groups. In a follow-up period of 18 months, bevacizumab was effective as a primary treatment in the treatment of severe cases of ROP. There was no significant difference between the two groups regarding the five areas and overall issues in follow-up intervals (P > 0.05). CONCLUSIONS: The obtained results did not show any growth and neurodevelopmental differences between treatment-naïve infants and those receiving IVB for the treatment of ROP. |
format | Online Article Text |
id | pubmed-8594208 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-85942082021-11-16 Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study Abrishami, Majid Boskabadi, Hassan Abrishami, Mojtaba Shekarchian, Farid Khadem-Rezaiyan, Majid Shoeibi, Nasser Int J Retina Vitreous Original Article BACKGROUND: The current study aimed to evaluate growth and neurodevelopmental status in patients with retinopathy of prematurity (ROP) treated with intravitreal bevacizumab (IVB). METHODS: This historical cohort study was conducted on neonates with ROP who were treated with IVB and age and birth weight-matched controls who did not need IVB. Apgar score less than five, history of blood transfusion and history of infectious diseases were among exclusion criteria. Indirect ophthalmoscopic examinations were performed till complete retinal vascularization. Growth and neurodevelopmental status were evaluated by Age and Stages Questionnaire (ASQ) at the ages of 6, 12, and 18 months. Developmental milestones were assessed in five areas (gross motor, fine motor, personal-social status, problem-solving, and relationship) and overall issues. RESULTS: A total of 34 cases and 36 controls were included in the present study. Birth weight and corrected gestational age were not statistically different between the groups. In a follow-up period of 18 months, bevacizumab was effective as a primary treatment in the treatment of severe cases of ROP. There was no significant difference between the two groups regarding the five areas and overall issues in follow-up intervals (P > 0.05). CONCLUSIONS: The obtained results did not show any growth and neurodevelopmental differences between treatment-naïve infants and those receiving IVB for the treatment of ROP. BioMed Central 2021-11-16 /pmc/articles/PMC8594208/ /pubmed/34784985 http://dx.doi.org/10.1186/s40942-021-00340-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Original Article Abrishami, Majid Boskabadi, Hassan Abrishami, Mojtaba Shekarchian, Farid Khadem-Rezaiyan, Majid Shoeibi, Nasser Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study |
title | Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study |
title_full | Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study |
title_fullStr | Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study |
title_full_unstemmed | Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study |
title_short | Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study |
title_sort | growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594208/ https://www.ncbi.nlm.nih.gov/pubmed/34784985 http://dx.doi.org/10.1186/s40942-021-00340-6 |
work_keys_str_mv | AT abrishamimajid growthandneurodevelopmentalstatusinpatientswithretinopathyofprematuritytreatedwithintravitrealbevacizumabacasecontrolstudy AT boskabadihassan growthandneurodevelopmentalstatusinpatientswithretinopathyofprematuritytreatedwithintravitrealbevacizumabacasecontrolstudy AT abrishamimojtaba growthandneurodevelopmentalstatusinpatientswithretinopathyofprematuritytreatedwithintravitrealbevacizumabacasecontrolstudy AT shekarchianfarid growthandneurodevelopmentalstatusinpatientswithretinopathyofprematuritytreatedwithintravitrealbevacizumabacasecontrolstudy AT khademrezaiyanmajid growthandneurodevelopmentalstatusinpatientswithretinopathyofprematuritytreatedwithintravitrealbevacizumabacasecontrolstudy AT shoeibinasser growthandneurodevelopmentalstatusinpatientswithretinopathyofprematuritytreatedwithintravitrealbevacizumabacasecontrolstudy |